Pharma Base S.A. Launches Osamine(TM) Pharmaceutical Grade Glucosamine in North America
PFAFFIKON, Switzerland, April 24 - Pharma Base S.A.
announces the launch of Osamine(TM) Pharmaceutical Grade Glucosamine for
the North American Dietary Supplement, Personal Care and Food industries.
Available as both Glucosamine Hydrochloride and Glucosamine Sulphate,
Osamine(TM) brings forward high quality pharmaceutical grade glucosamine to
the worldwide marketplace.
“With a greater focus on ingredient quality and a strong demand for raw
material sources [...]
Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
SAN FRANCISCO, April 24 - Antipodean Pharmaceuticals,
Inc. announced today, at the European Meeting for the Study of the Liver
(EASL), the positive results of a Phase 2 trial of its lead compound
MitoQ(R) (mitoquinone) in liver disease. The trial, conducted by Dr. Edward
Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at
Auckland City Hospital, successfully met the [...]
Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, April 24
- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global
specialty biopharmaceutical company, announces the acquisition of
arylsulfatase -A (ASA) an Enzyme Replacement Therapy (ERT) in Phase 1-2
clinical trials for Metachromatic Leukodystrophy (MLD) from the Danish
company Zymenex A/S (Zymenex).
MLD is a serious, life-limiting disease in which patients experience
progressive irreversible neurological damage. [...]
Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
PATERSON, N.J., April 24 - Amneal Pharmaceuticals, LLC is
pleased to announce the execution of an Asset Purchase Agreement for
Amneal’s wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,
to acquire the assets, facilities and business of Interpharm. The
acquisition includes Interpharm’s facilities on Long Island, New York as
well as the intellectual property including ANDA’s, technology and
processes.
Amneal will use [...]
Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
PATERSON, N.J., April 24 - Amneal Pharmaceuticals, LLC is
pleased to announce the execution of an Asset Purchase Agreement for
Amneal’s wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,
to acquire the assets, facilities and business of Interpharm. The
acquisition includes Interpharm’s facilities on Long Island, New York as
well as the intellectual property including ANDA’s, technology and
processes.
Amneal will use [...]
FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
CINCINNATI and BRIDGEWATER, N.J., April 24 -
The U.S. Food and Drug Administration (FDA) approved a new once-a-month
dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment
and prevention of postmenopausal osteoporosis. Actonel is approved to
reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study [...]
Watson Files FDA Application for Generic FENTORA(R)
CORONA, Calif., April 24 - Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, today confirmed that its subsidiary Watson Laboratories, Inc. (a
Nevada Corporation) has filed an Abbreviated New Drug Application (ANDA)
with the U.S. Food and Drug Administration (FDA) seeking approval to market
its Fentanyl Buccal Tablets C-II product prior to the expiration of patents
owned by Cephalon, Inc. [...]
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., April 24
- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies
have received a positive opinion for RELISTOR(TM) (methylnaltrexone
bromide) subcutaneous injection from the Committee for Medicinal Products
for Human Use (CHMP), the scientific committee of the European Medicines
Agency (EMEA). The companies are seeking [...]
Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
ALLEGAN, Mich., April 24 - The Perrigo Company
(Nasdaq: PRGO; TASE) today announced that it has received approval from the
U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC)
Nicotine Polacrilex Gum USP, 2 mg (base) and 4 mg (base) (Orange, Coated).
The FDA has determined the product to be bioequivalent to the reference
listed drug, GlaxoSmithKline’s Nicorette(R) Gum, [...]
Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Children’s Hospital Foundation for $182 Million
NEW YORK, April 24 - The Children’s Hospital Foundation,
the parent company of The Children’s Hospital of Philadelphia(R), and
Royalty Pharma announced today that the Foundation has sold its worldwide
royalty interest in respect of sales of RotaTeq(R) from and after October
1, 2007, to Royalty Pharma for $182 million in cash.
”With the addition of this royalty on RotaTeq(R), we [...]
